Trial Profile
Relationship between everolimus discontinuation or dose reduction because of stomatitis or cutaneous toxicity and clinical outcome in patients with metastatic renal cell carcinoma
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 17 Aug 2015
Price :
$35
*
At a glance
- Drugs Everolimus (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions; Therapeutic Use
- 17 Aug 2015 New trial record